Analysts expect AEON Biopharma to report a Q2 2026 loss of $0.33 per share on zero revenue, reflecting its status as a clinical-stage biotechnology firm. The stock currently trades around $0.28, significantly below the average analyst price target of $4.80, which suggests massive potential upside if clinical milestones are met.
Investors are primarily focused on the clinical progress of ABP-450, specifically recent data demonstrating its structural and functional biosimilarity to Botox. Additionally, the market is monitoring AEON's liquidity position following a July 2026 public offering that raised $13.6 million, enabling the company to regain compliance with NYSE American listing standards.